This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Niitsu, N. Articles by Hirano, M. Search for Related Content PubMed PubMed Citation Articles by Niitsu, N. Articles by Hirano, M.

Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma

The Adult Lymphoma Treatment Study Group (ALTSG). ¹ Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa; ² Department of Clinical and Laboratory Medicine, Wakayama Medical University, Wakayama; ³ Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; and ⁴ Saitama Cancer Center Research Institute, Saitama, Japan

Purpose: Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin’s lymphoma.

Experimental Design: We used immunohistochemistry to examine the expression of nm23-H1 by the lymphoma cells in patients with diffuse large B-cell lymphoma (DLBCL).

Results: By analyzing a consecutive series of 172 untreated DLBCL patients, we found that 100 (58.1%) were strongly positive. The cytoplasmic nm23 expression in lymphoma cells correlated significantly with the serum nm23-H1 level. There was a significant correlation between patients with cytoplasmic nm23-positive lymphoma and those with performance status 2–4, stage III/IV, bulky mass, B symptoms, elevated serum level of soluble interleukin 2 receptor, and elevated serum level of C-reactive protein. Overall and progression-free survival rates were significantly lower in patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas. Similar difference was seen between patients with high and low serum levels of nm23-H1. Thus, the correlation between presence or absence of cytoplasmic nm23-H1 expression and serum nm23-H1 levels suggests that serum nm23-H1 is produced directly by lymphoma cells.

Conclusion: We suggest that nm23-H1 expression is a prognostic factor for DLBCL, and that it is as important as serum nm23-H1, both of which are useful for planning a treatment strategy.

This article has been cited by other articles:

				N. Niitsu, H. Nakamine, M. Okamoto, J.-i. Tamaru, and M. Hirano A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma Ann. Onc., November 1, 2008; 19(11): 1941 - 1946. [Abstract] [Full Text] [PDF]

				N Niitsu, M Okamoto, N Nakamura, H Nakamine, M Bessho, and M Hirano Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma Ann. Onc., July 1, 2007; 18(7): 1203 - 1208. [Abstract] [Full Text] [PDF]

				I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF]